Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, an... Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, and acquisitions. The company's pipeline consists of product candidates targeting hepatitis B virus, or HBV, influenza A, human immunodeficiency virus, or HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue and license revenue. Show more
Fast Track designation follows positive preliminary Phase 2 trial data presented at the European Association for the Study of the Liver Congress 2024 and underscores the unmet need for people...
– Preliminary Phase 2 SOLSTICE trial data reinforce the potential of both regimens to be transformative treatments in an area of high unmet medical need – – Conference call scheduled for June 5...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.28 | -3.06681270537 | 9.13 | 9.4125 | 8.76 | 961096 | 9.08424408 | CS |
4 | -1.79 | -16.8233082707 | 10.64 | 13.09 | 8.68 | 1734640 | 10.13373024 | CS |
12 | -0.66 | -6.94006309148 | 9.51 | 13.09 | 7.61 | 1160219 | 9.74535014 | CS |
26 | -1.15 | -11.5 | 10 | 13.09 | 7.61 | 1114719 | 9.97211684 | CS |
52 | -15.56 | -63.7443670627 | 24.41 | 24.99 | 7.61 | 1254840 | 10.713768 | CS |
156 | -34.87 | -79.7575480329 | 43.72 | 58 | 7.61 | 1180674 | 23.35681559 | CS |
260 | -7.3 | -45.2012383901 | 16.15 | 141.01 | 7.61 | 1137775 | 29.89871945 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.